Pharmaceutical sales: approx. 55%
Medical technology sales: approx. 30%
Consumer goods sales: approx. 15%

TOP 3 markets:
USA: approx. 45%
Europe: approx. 25%
Asia-Pacific: approx. 20%

Johnson & Johnson generates the majority of its sales from the pharmaceutical sector, followed by medical technology and consumer goods. The USA is the largest individual market, followed by Europe and the Asia-Pacific region. This distribution reflects the company's strong market presence and diversified product portfolio.

Production Sites: Worldwide, with main locations in the USA, Europe, and Asia.

Johnson & Johnson is a globally operating company that produces its products at various locations worldwide. The main production sites are located in the USA, especially in New Jersey, where the company is headquartered.

In Europe, Johnson & Johnson has significant production facilities in countries such as Ireland, Belgium, and Switzerland. These locations are strategically chosen to efficiently serve the European market.

In Asia, the company operates production sites in countries like China, India, and Singapore. These sites support the growing demand in the Asian markets and enable Johnson & Johnson to benefit from the cost advantages of the region.

This global presence allows Johnson & Johnson to distribute its products efficiently and to flexibly respond to regional market requirements.

Revenue Growth: Estimated 4-6% annually (2025 forecast)

Focus Areas: Pharmaceuticals, Medical Technology, Consumer Goods

Johnson & Johnson pursues a diversified growth strategy focusing on strengthening and expanding its three main business areas: Pharmaceuticals, Medical Technology, and Consumer Goods.

In the pharmaceutical sector, the company is focusing on developing new drugs and therapies, particularly in the fields of oncology, immunology, and neuroscience. Through strategic partnerships and acquisitions, J&J aims to expand its product pipeline and accelerate the market introduction of innovative therapies.

In the medical technology sector, the focus is on digitizing and automating healthcare solutions. J&J is investing in technologies such as robotics and AI to develop more efficient and precise medical devices.

In the consumer goods segment, the company aims to gain market share through sustainable and health-oriented products. Introducing environmentally friendly packaging and adapting to changing consumer preferences are central elements of this strategy.

Additionally, J&J is focusing on geographical expansion, particularly in emerging markets, to maximize growth potential in these regions.

Main raw materials: Chemicals, pharmaceutical ingredients, packaging materials

Countries of origin: China, India, Germany, USA

Johnson & Johnson imports a variety of raw materials and materials necessary for the production of their products. These include in particular chemical raw materials and pharmaceutical ingredients, which are sourced from countries such as China and India. These countries are known for their extensive production of pharmaceutical ingredients.

Packaging materials and other specialized materials are often imported from the USA and Germany, as these countries have a highly developed manufacturing industry that meets Johnson & Johnson's high quality standards.

Diversifying supply chains is crucial for Johnson & Johnson to ensure supply security and minimize risks in the supply chain.

Market Capitalization: approx. 450 billion USD (estimated for 2025)
Research and Development Expenditure: approx. 12 billion USD (estimated for 2025)
Dividend Yield: approx. 2.5% (estimated for 2025)

Johnson & Johnson has a significant competitive advantage, which is composed of several factors. Firstly, the company has a strong brand recognition and a diversified product portfolio in the pharmaceuticals, medical devices, and consumer goods sectors. This diversification enables the company to minimize market risks and benefit from various growth opportunities.

Secondly, Johnson & Johnson continuously invests substantial amounts in research and development, strengthening the company's innovation power and leading to the introduction of new products. These investments are crucial to remain competitive in the fiercely contested healthcare sector.

Finally, Johnson & Johnson benefits from a solid financial position, allowing the company to make strategic acquisitions and further expand its market position. The stable dividend policy also underscores the company's confidence in its long-term earning power.

Institutional investor share: approx. 70% (estimated for 2025)
Insider purchases/sales: No significant changes reported (2025)

The institutional investor share in Johnson & Johnson traditionally stands at around 70%, indicating the trust of institutional investors in the stability and long-term value creation of the company. These investors include large investment funds, pension funds, and other institutional investors who typically have a long-term perspective.

Regarding insider purchases and sales, there have been no significant changes or unusual activities highlighted in the recent reports. This suggests that the management and insiders have a stable confidence in the current and future performance of the company.

Market share of Johnson & Johnson: approx. 9% (2025, estimated)

Top competitors and their market shares:

1. Pfizer Inc. - approx. 11%
2. Roche Holding AG - approx. 10%
3. Johnson & Johnson - approx. 9%
4. Novartis AG - approx. 8%
5. Merck & Co., Inc. - approx. 7%
6. Sanofi S.A. - approx. 6%
7. GlaxoSmithKline plc - approx. 5%
8. AbbVie Inc. - approx. 5%
9. AstraZeneca plc - approx. 4%
10. Bayer AG - approx. 4%

Moat of Johnson & Johnson:

Johnson & Johnson possesses a significant moat, which is manifested by several factors. Firstly, the company has a strong brand recognition and a diversified product portfolio that includes both consumer goods and pharmaceuticals and medical devices. This provides a certain level of stability and risk diversification.

Secondly, Johnson & Johnson continuously invests in research and development, leading to a robust pipeline of new products. This innovation strength enhances the market position and enables the company to differentiate itself from competitors.

Compared to other companies in the industry, Johnson & Johnson has the advantage of a broad and diversified business model, while some competitors are more focused on specific segments. This can be seen as an advantage as it allows the company to better absorb market changes.

However, some competitors, such as Pfizer and Roche, also have strong moats, especially through specialized research and patented medicines. These companies may have a competitive advantage in certain segments, particularly in oncology and innovative therapies.

Overall, Johnson & Johnson remains a strong company with a solid moat due to its size, diversification, and innovation, even though it faces challenges in certain areas from specialized competitors.

Revenue Growth (2024): 4.5%
Research and Development Expenses (2024): $12.2 billion
Market Share in the Pharmaceutical Sector (2024): 8%

Johnson & Johnson is known for its stable market position and diversification in the pharmaceuticals, medical devices, and consumer goods sectors. In 2024, the company experienced a revenue growth of 4.5%, driven by strong demand in the pharmaceuticals and medical devices sectors.

Investments in research and development amounted to $12.2 billion, highlighting the company's innovation capabilities. This is particularly important as new products and therapies are crucial for future growth.

With an 8% market share in the pharmaceutical sector, Johnson & Johnson remains a significant player in the industry. This strong position, combined with a solid balance sheet and a proven ability to adapt to market changes, speaks to the long-term attractiveness of the stock as an investment.

However, investors should keep an eye on regulatory risks and competition in the pharmaceutical sector, as these factors could impact future performance.

Dividend yield: 2.8% (estimated for 2025)
Dividend growth: 6% annually (average over the last 5 years)
Payout ratio: 50% (estimated for 2025)

Johnson & Johnson is known for its reliable dividend policy and is one of the so-called "Dividend Aristocrats," companies that have continuously increased their dividends for over 25 years.

The dividend yield of about 2.8% for 2025 is attractive compared to other large companies and reflects the stable financial situation of the company. With a payout ratio of around 50%, there is enough room for reinvestments and future dividend increases.

The continuous dividend growth of an average of 6% annually demonstrates Johnson & Johnson's commitment to providing shareholders with steady value appreciation. The strong balance sheet and diversification in various health sectors support the reliability of dividend payments.